| Literature DB >> 35672349 |
Fardad Faress1, Amin Yari2, Fereshteh Rajabi Kouchi3, Ava Safari Nezhad4, Alireza Hadizadeh5,6, Leili Sharif Bakhtiar7, Yousef Naserzadeh8, Niloufar Mahmoudi8.
Abstract
This study introduces a universal correlation based on the modified version of the Arrhenius equation to estimate the solubility of anti-cancer drugs in supercritical carbon dioxide (CO2). A combination of an Arrhenius-shape term and a departure function was proposed to estimate the solubility of anti-cancer drugs in supercritical CO2. This modified Arrhenius correlation predicts the solubility of anti-cancer drugs in supercritical CO2 from pressure, temperature, and carbon dioxide density. The pre-exponential of the Arrhenius linearly relates to the temperature and carbon dioxide density, and its exponential term is an inverse function of pressure. Moreover, the departure function linearly correlates with the natural logarithm of the ratio of carbon dioxide density to the temperature. The reliability of the proposed correlation is validated using all literature data for solubility of anti-cancer drugs in supercritical CO2. Furthermore, the predictive performance of the modified Arrhenius correlation is compared with ten available empirical correlations in the literature. Our developed correlation presents the absolute average relative deviation (AARD) of 9.54% for predicting 316 experimental measurements. On the other hand, the most accurate correlation in the literature presents the AARD = 14.90% over the same database. Indeed, 56.2% accuracy improvement in the solubility prediction of the anti-cancer drugs in supercritical CO2 is the primary outcome of the current study.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35672349 PMCID: PMC9174250 DOI: 10.1038/s41598-022-13233-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Literature data for solubility of anti-cancer drugs in supercritical carbon dioxide.
| CO2 (1) + drug (2) | Temperature (K) | Pressure (MPa) | CO2 density (kg/m3) | Drug solubility* × 106 | No. data |
|---|---|---|---|---|---|
| Sorafenib tosylate[ | 308–338 | 12–27 | 388–914 | 0.68–12.57 | 24 |
| Sunitinib malate[ | 308–338 | 12–27 | 388–914 | 5–85.6 | 24 |
| Azathioprine[ | 308–338 | 12–27 | 388–914 | 2.7–18.3 | 24 |
| Busulfan[ | 308–338 | 12–40 | 383–971 | 32.7–865 | 32 |
| Tamoxifen[ | 308–338 | 12–40 | 383–971 | 18.8–989 | 32 |
| Letrozole[ | 318–348 | 12–36 | 319–922 | 1.6–85.1 | 20 |
| Tamsulosin[ | 308–338 | 12–27 | 384–914 | 0.18–10.13 | 24 |
| Capecitabine[ | 308–348 | 15.2–35.4 | 477–955 | 2.7–158.8 | 40 |
| Paclitaxel[ | 308–328 | 10–27.5 | 654–915 | 1.2–6.2 | 21 |
| 5-Fluorouracil[ | 308–328 | 12.5–25 | 541–901 | 3.8–14.6 | 18 |
| Thymidine[ | 308–328 | 10–30 | 325–928 | 1.2–8 | 25 |
| Decitabine[ | 308–338 | 12–40 | 383–971 | 28.4–1070 | 32 |
Available empirical correlations for solute/drug solubility in supercritical carbon dioxide.
| Correlation | Formula | |
|---|---|---|
| Chrastil[ | Equation (1) | |
| Jouyban et al.[ | Equation (2) | |
| Kumar and Johnstone[ | Equation (3) | |
| Garlapati and Madras[ | Equation (4) | |
| Bian et al.[ | Equation (5) | |
| Bartle et al.[ | Equation (6) | |
| Méndez-Santiago and Teja[ | Equation (7) | |
| Sodeifian et al.[ | Equation (8) | |
| Tan et al.[ | Equation (9) | |
| Gordillo et al.[ | Equation (10) |
Figure 1Relevancy between the solubility of anti-cancer drugs in supercritical CO2 and temperature, pressure, and carbon dioxide density.
Figure 2Dependency of sorafenib tosylate solubility in the supercritical CO2 on the isobaric variation of temperature (the cartesian coordinate).
Figure 3The variation of sorafenib tosylate solubility in the SCCO2 by the solvent density (the cartesian coordinate).
Figure 4The effect of the inverse pressure on the sorafenib tosylate solubility in the SCCO2 (the semi-logarithm coordinate).
Adjusted coefficients of the proposed correlation for estimating the solubility of anti-cancer drugs in supercritical CO2.
| Drug | a1 × 10–6 | a2 × 10–6 | a3 × 10–6 | a4 | a5 × 10–6 | a6 × 10–6 |
|---|---|---|---|---|---|---|
| Sorafenib tosylate | 1.4247605573 | − 0.0500529210 | − 385.827674360 | 45.3662839688 | 0 | 0.349064452 |
| Sunitinib malate | 0.2647256734 | − 1.4200164959 | 1355.66373666 | 36.2840647550 | − 12.8796352 | 0 |
| Azathioprine | 0.9468557792 | − 0.0163521099 | − 266.098396089 | 24.1069578946 | 8.36900373 | − 4.83860672 |
| Busulfan | 60.280909168 | − 16.630567159 | − 1344.60675047 | 78.2721455261 | 76.7145899 | 0 |
| Tamoxifen | 144.11848954 | − 42.703480295 | − 1974.01401538 | 99.6434546809 | 41.05460792 | 6.14532671 |
| Letrozole | 8.7649418657 | − 2.9569956441 | 4.94014077630 | 80.8669042062 | 4.145085191 | − 0.53838515 |
| Tamsulosin | 0.7923204828 | 0.1478689559 | − 368.263373717 | 35.1646118112 | 0 | 2.51134612 |
| Capecitabine | 48.093681561 | − 12.750147899 | − 2037.79351684 | 123.522295303 | 17.1813407 | − 8.09385756 |
| Paclitaxel | 0.0068347581 | 0.0253752394 | − 6.61523852780 | 14.6087222619 | − 22.8448049 | 17.3239309 |
| 5-Fluorouracil | 0.5186887168 | − 0.1340640969 | − 1.39609503380 | 44.0728502801 | − 10.2690278 | 11.7076100 |
| Thymidine | 0.2122407854 | 0.0094685158 | − 70.3123673279 | 18.0254848942 | − 2.51330781 | 3.01138517 |
| Decitabine | 117.68771002 | − 10.092201917 | − 25,295.9332530 | 74.7951605316 | 48.3284747 | 0 |
Uncertainty of the proposed model and available correlations in the literature in terms of AARD% (the italicized cells are calculated in the current study; the bold font values show the most accurate predictions).
| Drug | Empirical correlation | |||||
|---|---|---|---|---|---|---|
| Modified Arrhenius | Chrastil[ | Jouyban et al.[ | Kumar and Johnston[ | Garlapati and Madras[ | ||
| Sorafenib tosylate | 13.90[ | 14.40[ | 12.70[ | 11.00[ | ||
| Sunitinib malate | 21.26[ | 14.20[ | 17.16[ | |||
| Azathioprine | 9.88[ | 10.21[ | 8.62[ | |||
| Busulfan | 11.20[ | 7.57[ | 11.20[ | |||
| Tamoxifen | 16.50[ | 11.10[ | 16.40[ | |||
| Letrozole | 22.16 | 21.50[ | ||||
| Tamsulosin | 22.11[ | 15.20[ | ||||
| Capecitabine | 12.20[ | 11.90[ | 10.30[ | |||
| Paclitaxel | ||||||
| 5-Fluorouracil | ||||||
| Thymidine | ||||||
| Decitabine | 15.30[ | 9.04[ | 15.30[ | |||
| Overall | 17.42 | 56.51 | 18.97 | 19.64 | ||
Figure 5Outcome of the ranking analysis on the accuracy of the developed correlation and those available in the literature.
Figure 6Overall ranking of the considered correlations to predict the solubility of anti-cancer drugs in supercritical carbon dioxide.
Figure 7Cross-plot of the modified Arrhenius predictions versus experimental measurements for anti-cancer drug solubility in supercritical CO2.
Figure 8The observed relative deviations for estimating each experimental measurement of anti-cancer drug solubility in supercritical carbon dioxide.
Figure 9Differentiating between valid and suspect data collected from the literature.
Figure 10Numbers of detected outliers for the considered anti-cancer drugs.
Figure 11Variation of the sunitinib malate solubility in the supercritical CO2 as a function of operating pressure and temperature.
Figure 12The effect of pressure and temperature on the thymidine solubility in the supercritical carbon dioxide.
Figure 13The highest amount of drug solubility in SCCO2 at temperature = 318 K.
Figure 14The smallest amount of drug solubility in SCCO2 at temperature = 318 K.
Figure 15Effect of operating conditions on the busulfan solubility in SCCO2 (open circle: 338 K, open rectangle: 328 K, six pointed filled star: 318 K, four pointed filled star: 308 K, dashed lines modified Arrhenius predictions).